Symbols

SEEL(Delisted)

Seelos Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 4

Low Cash Short-term Debt Ratio

Price Hits New Low

Price Hits 52-week Low

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SEEL

Seelos Therapeutics, Inc.

A biopharmaceutical company focused on developing novel treatments for rare diseases and central nervous system disorders

Industry

Established Date

Listing Date

04/26/2000

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.seelostherapeutics.com

Security Type

Common stock

Office address

300 Park Avenue, 2nd Floor, New York, NY 10022

Business

Introduction

Seelos Therapeutics, Inc., was incorporated in Nevada in 1987. The company and its affiliates have been present in the pharmaceutical industry since 1995. As a pharmaceutical company, it is focused on achieving efficient development of products to address significant unmet needs in central nervous system (" CNS ") diseases and rare diseases. The company's product development has leveraged NexACT's proprietary penetration enhancement technology. The company's initial product is Canadian-approved Vitaros for the treatment of erectile dysfunction; the latter online late-stage product candidate, Femprox, for the treatment of female sexual arousal disorder. The company has applied to Switzerland for decentralized approval, hoping that Vitaros can be used in Europe to treat ED. Femprox has completed Phase III clinical trials in China. The company is submitting more clinical trial regulatory plans to the US, Canada and Europe.

Company Financials

EPS

SEEL has released its 2023 Q3 earnings. EPS was reported at -3.6, versus the expected -1.8, missing expectations. The chart below visualizes how SEEL has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SEEL has released its 2024 Q2 earnings report, with revenue of 376.00K, reflecting a YoY change of 11.90%, and net profit of 1.71M, showing a YoY change of 105.80%. The Sankey diagram below clearly presents SEEL's revenue sources and cost distribution.